Brazil’s health care regulator Anvisa handed out the nation’s first license for the sale of a cannabis-based drug – one designed for the treatment of multiple sclerosis.
According to Reuters, U.K.-based GW Pharmaceuticals PLC developed the marijuana-based oral spray, which is known internationally as Sativex. It will be marketed in Brazil as Mevatyl.
Anvisa announced Monday that it had issued a license to São Paulo-based Beaufour Ipsen Farmacêutica to sell and distribute the drug.
Sativex is already sold in 28 other countries, according to Anvisa.
For several years, Brazilian patients have waged a legal battle to get around
Brazil allows sale of cannabis-based MS drug is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs